Morbidity and mortality of pancreatic tumors undergoing surgical treatment

Zeni, L.B.; Russi, Ricardo Fantazzini; Fialho, Alexandre Faleiro; Fonseca, Ana Luiza Pagani; Sombrio, Lyara Schaefer; Rocha, Igor Cunha

doi:10.1590/s0102-67202014000400011

Cited by 18 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…to pancreatic cancer in men, with 156,000 deaths in women. In developed countries, mortality rates are 7-9/100,000 in men and 4,5-6/100,000 in women (2,13) . The results presented herein showed that Brazilian mortality rates follow the behavior observed in developed countries.…”

Section: Resultsmentioning

confidence: 99%

Pancreatic Cancer in Brazil: Mortality Trends and Projections Until 2029

Barbosa

Santos

Souza

2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: Pancreatic cancer is one of the main cancer-related causes of death in developed countries, and one of the most lethal malignant neoplasms. This type of cancer is classified as the ninth most frequent in the world. OBJECTIVE: Analyze temporal trends for pancreatic cancer in Brazil in the period 2000-2014 and calculate mortality projections for the period 2015-2029. METHODS: Ecological study, with temporal series, based on information provided by the Brazilian Mortality Information System. Analysis included deaths due to pancreatic malignant neoplasms in Brazil in the period 2000-2014, and analyzed according to sex, age group and Brazilian geographic regions. Projections were made until 2029 in five-year periods, calculated in Nordpred (within the R software). Mortality trends were analyzed by Joinpoint regression. RESULTS: Between 2000 and 2014, there were 112,533 deaths due to pancreatic cancer in Brazil. Age-standardised rates was 5.1 deaths/100,000 men and 3.81 deaths/100,000 women. The highest rates were registered for the Midwest region, for both genders. Projections indicated that for the five-year period 2025-2029 there will be increased mortality rates for men in the Northeast and Midwest regions. Joinpoint analysis for Brazil did not reveal significant increases for women (APC=0.4%; 95% CI: -0.2; 1.0), however, there was a significant increasing mortality trend for men (APC= 3.7%; 95% CI: 0.6-7.0) in the period 2000-2004, followed by a stable period, an then another period of significant increases after 2010. These figures are mostly explained by variations in the Brazilian demographic structure. CONCLUSION: Pancreatic cancer mortality is unequally distributed across Brazilian regions and genders, and during the next two decades the differences will be accentuated.

show abstract

Section: Resultsmentioning

confidence: 99%

Pancreatic Cancer in Brazil: Mortality Trends and Projections Until 2029

Barbosa

Santos

Souza

2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…This is because many patients do not experience symptoms until the disease is in an advanced stage, leading to delay in initiation of treatment 8 . Late presentation, tumor aggressiveness, difficult surgical resection, and availability of few effective systemic therapies contribute to the poor clinical outcome of pancreatic adenocarcinoma 9 . Egypt, as in many other developing countries, has little countrywide descriptive epidemiology about cancer including exocrine pancreatic adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

Clinical Outcome of Exocrine Pancreatic Adenocarcinoma: A Single Center Experience

Gohar

Megahid

Rizk

et al. 2017

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Background: Pancreatic carcinoma is an uncommon tumor with a high mortality rate. Because of the late presentation of the disease, only a small percent of patients are candidate for surgery. Aim: To assess the epidemiology and the clinical outcome of patients diagnosed with pancreatic adenocarcinoma presented to the Clinical Oncology Department at Menoufia University. Methods: All patients presenting with exocrine pancreatic carcinoma from January 2007 to December 2011 were included. Epidemiological features of patients and their treatment details and outcome were collected retrospectively from the medical records. An equal number of matched controls were interviewed and filled a questionnaire to identify possible risk factors. Results: Exocrine pancreatic adenocarcinoma represented 1.4 % of all cancer patients treated at our institution. The study included 76 patients and 76 controls. Pancreatic cancer patients were significantly more likely to be overweight when compared to controls (OR= 2.51, 95%CI: 1.04-6.06). Diabetes mellitus and smoking were significantly more prevalent among patients (OR= 2.36, 95%CI: 1.23-4.54; OR= 2, 95%CI: 1.05-3.81; respectively). The median time to progression was 12 weeks (95%CI: 9.46-14.53) and the median overall survival was 16 weeks (95%CI: 12.22-19.78). Patients with earlier tumor stage and those who underwent surgery followed by adjuvant chemotherapy had significantly better overall survival (p=0.02 and <0.001, respectively). Conclusion: Exocrine pancreatic adenocarcinoma is an uncommon tumor among cancer patients treated at the Clinical Oncology Department of Menoufia University. Diabetes mellitus, higher body mass index and smoking are significantly more prevalent in pancreatic carcinoma patients. Earlier tumor stage and undergoing surgery followed by chemotherapy are associated with statistically significant better overall survival.

show abstract

“…Pancreatic cancer is the twelfth most common type of cancer (2% of the total cases) and the seventh cause of cancer deaths worldwide [ 94 , 95 ]. Pancreatic cancer is not nearly as prevalent as lung or prostate cancers; however, pancreatic tumors are extremely aggressive, leading to the worst prognosis for any kind of cancer, with a five-year survival rate of ~5% [ 96 , 97 ]. Both exocrine and endocrine cells of the pancreas can form cancers, but those formed by exocrine cells are described to be much more common and aggressive [ 98 , 99 ].…”

Section: Microbiome and Pancreatic Cancermentioning

confidence: 99%

Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies

Leal-Lopes

Velloso

Campopiano

et al. 2015

Journal of Diabetes Research

View full text Add to dashboard Cite

The pancreas plays a central role in metabolism, allowing ingested food to be converted and used as fuel by the cells throughout the body. On the other hand, the pancreas may be affected by devastating diseases, such as pancreatitis, pancreatic adenocarcinoma (PAC), and diabetes mellitus (DM), which generally results in a wide metabolic imbalance. The causes for the development and progression of these diseases are still controversial; therefore it is essential to better understand the underlying mechanisms which compromise the pancreatic homeostasis. The interest in the study of the commensal microbiome increased extensively in recent years, when many discoveries have illustrated its central role in both human physiology and maintenance of homeostasis. Further understanding of the involvement of the microbiome during the development of pathological conditions is critical for the improvement of new diagnostic and therapeutic approaches. In the present review, we discuss recent findings on the behavior and functions played by the microbiota in major pancreatic diseases and provide further insights into its potential roles in the maintenance of pancreatic steady-state activities.

show abstract

Morbidity and mortality of pancreatic tumors undergoing surgical treatment

Cited by 18 publications

References 24 publications

Pancreatic Cancer in Brazil: Mortality Trends and Projections Until 2029

Pancreatic Cancer in Brazil: Mortality Trends and Projections Until 2029

Clinical Outcome of Exocrine Pancreatic Adenocarcinoma: A Single Center Experience

Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies

Contact Info

Product

Resources

About